7 stories mentioning MDGLUpdated 12d ago
Every FINWIRES story that references MDGL, newest first.
Madrigal Pharmaceuticals (MDGL) has an average rating of buy and mean price target of $680, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
William John Sibold, Director, President and Chief Executive Officer, on July 17, 2026, sold 2,500 shares in Madrigal Pharmaceuticals (MDGL) for $1,368,253. Following the Form 4 filing with the SEC, Sibold has control over a total of 209,329 common shares of the company, with 209,329 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/xslF345X05/wk-form4_1784596610.xml
Madrigal Pharmaceuticals (MDGL) announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.Truist kept its buy rating with a price target of $709.Price: $533.16, Change: $-3.54, Percent Change: -0.66%
Healthcare stocks were mixed in early trading Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down by 0.2% and the iShares Biotechnology ETF (IBB) 1.4% lower.Moderna (MRNA) shares fell 1.2%, extending the 10.8% loss in the previous session. Jefferies lifted its price target on the company to $60 from $53, while maintaining a hold rating.Madrigal Pharmaceuticals (MDGL) traded down 0.5% after a 4.2% fall at the end of Friday's session. The company said that the US Patent and Trademark Office has issued three new patents covering resmetirom, strengthening its intellectual property portfolio for Rezdiffra.InMode (INMD) stock was down more than 1% after rising 1.8% at the prior close. The company reported preliminary Q2 revenue of $95.2 million to $95.4 million.
Madrigal Pharmaceuticals (MDGL) said Wednesday that a new analyses of phase 3 trial data and real-world evidence showed that Rezdiffra reduced markers of cardiovascular and liver-related risk in patients with metabolic dysfunction-associated steatohepatitis (MASH).The drug improved atherogenic lipid profiles associated with cardiovascular risk, according to a secondary analysis of phase 3 data, the company said.In patients with well-compensated MASH cirrhosis, Rezdiffra also improved a risk score that predicts the probability of experiencing severe liver-related events, Madrigal said.Price: $532.02, Change: $+7.74, Percent Change: +1.48%
Richard S Levy, Director, on May 22, 2026, sold 5,682 shares in Madrigal Pharmaceuticals (MDGL) for $2,928,716. Following the Form 4 filing with the SEC, Levy has control over a total of 22,015 common shares of the company, with 22,015 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1157601/000162828026037830/xslF345X05/wk-form4_1779487311.xml
Arrowhead Pharmaceuticals (ARWR) said Tuesday it has signed an agreement with Madrigal Pharmaceuticals (MDGL) to exclusively license its ARO-PNPLA3 program, which is evaluating a potential treatment for metabolic dysfunction-associated steatohepatitis, or MASH.Under the agreement, Arrowhead said that Madrigal will receive a global license to develop, manufacture, and commercialize ARO-PNPLA3, which uses the TRiM platform to silence hepatocyte expression of patatin-like phospholipase domain-containing 3, or PNPLA3, as a potential treatment for patients with MASH.When the deal closes, Arrowhead said it will receive a $25 million upfront payment and be eligible to receive up to an additional $975 million upon meeting development, regulatory, and sales milestones.Arrowhead said it is also eligible to receive tiered royalties on commercial sales ranging from high single digits to the mid-teens.Price: $76.58, Change: $+0.19, Percent Change: +0.25%
